Targeting CTLA-4 overcomes tumor microenvironmental resistance to enhance efficacy of Radiotherapy and αCD40mAb therapy in prostate cancer
Ontology highlight
ABSTRACT: This study explored the potential for agonistic α CD40mAb to enhance T-cell responses in combination with RT in prostate tumours which are resistant to RT and immune checkpoint inhibitor combination. Tumour bearing mice were treated with radiotherapy (3x8Gy) on days 0,1,2 and a α CD40mAb administered days 7,10, 14. Tumour samples were collected on day 15, and immunological changes in the microenvironment profiled using Nanostring (n-counter) PAN cancer immune profiling panel.
INSTRUMENT(S): NanoString nCounter
ORGANISM(S): Mus musculus
SUBMITTER:
PROVIDER: E-MTAB-11105 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA